Abstract:SummaryBackgroundAlthough the current consensus recommends a standard treatment of high-dose intravenous immunoglobulin with high-dose aspirin to manage Kawasaki disease (KD), the use of different adjunctive therapies remains controversial. The aim of the current network meta-analysis (NMA) was to compare the efficacy and tolerability of different existing interventions for the initial and refractory stages of KD.MethodsAn NMA of randomised controlled trials (RCTs) was conducted using the frequentist model applied after electronic searches in PubMed, Embase, ScienceDirect, ProQuest, ClinicalTrials.gov, ClinicalKey, Cochrane CENTRAL, and Web of Science. The main outcomes were reduced fever duration/diminished severity of fever subsided. The initial stage of KD was defined as the first stage to treat patients with KD; the refractory stage of KD represents KD patients who failed to respond to standard KD treatment. The cut-off points for intravenous immunoglobulin (IVIG) were low (100–400 mg), medium (1 g), and high (at least 2 g).FindingsA total of fifty-six RCTs with 6486 participants were included. NMA demonstrated that the medium-dosage IVIG + aspirin + infliximab [mean difference=−1.76 days (95% confidence intervals (95% CIs): −3.65 to 0.13 days) compared to high-dosage IVIG + aspirin] exhibited the shortest fever duration; likewise, the medium-dosage IVIG + aspirin + infliximab [odds ratio (OR)=0.50, 95% CIs: 0.18–1.37 compared to high-dosage IVIG + aspirin] exhibited the smallest incidence of coronary artery lesion (CAL) in the initial-stage KD. In the refractory-stage KD, the high-dosage IVIG + pulse steroid therapy (OR=0.04, 95% CIs: 0.00–0.43 compared to the high-dosage IVIG only) had the best rate of decline of fever; likewise, the high-dosage IVIG + ciclosporin [OR=0.05 (95% CIs: 0.00–1.21) compared to the high-dosage IVIG only] exhibited the smallest incidence of CAL. Infliximab significantly improved resolution compared to the high-dosage IVIG only group (OR=0.20, 95%CIs: 0.07–0.62) in refractory-stage KD.InterpretationThe NMA demonstrated that the combination therapy with the standard therapy of IVIG and aspirin might have an additional effect on shortening the duration of fever and lowering the CAL incidence rate in patients with acute KD. Moreover, the combination therapy with high-dose IVIG and pulse steroid therapy or cyclosporine therapy might have an additional effect on improving the rate of decline of fever and lowering the incidence rate of CAL in children with refractory KD. Because some of the findings of this NMA should be considered hypothesis-generating rather than confirmatory, further evidence from de novo randomised trials is needed to support our results.FundingNone.

EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ALONE ON CORONARY ARTERY LESION REDUCTION IN KAWASAKI DISEASE

What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis

The Safety and Effectiveness of Clopidogrel Versus Aspirin in Kawasaki Disease with Mild-to-moderate Liver Injury

Evaluation Of Intravenous Immunoglobulin Resistance And Coronary Artery Lesions In Relation To Th1/Th2 Cytokine Profiles In Patients With Kawasaki Disease

Treatment of Kawasaki Disease: A Network Meta-Analysis of Four Dosage Regimens of Aspirin Combined With Recommended Intravenous Immunoglobulin

Center of Diagnosis and Treatment of Intravenous Immunoglobulin-Refractory Kawasaki Disease

Randomized Trial of Different Initial Intravenous Immunoglobulin Regimens in Kawasaki Disease

A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: the Earlier, the Better?

Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial

Effects of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesions in Patients with Kawasaki Disease: Study Protocol for a Phase III Multicenter, Open-Label, Blinded-Endpoints Randomized Controlled Trial

A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials

Efficacy Between Low And High Dose Aspirin For The Initial Treatment Of Kawasaki Disease: Current Evidence Based On A Meta-Analysis

Risk Factors of Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease: A Meta-Analysis of Case-Control Studies

Clinical Analysis of Intravenous Immunoglobulin in the Patients with Kawasaki Disease

Clinic features and follow-up study of coronary artery lesion in children with Kawasaki disease

Therapy of Intravenous Gamma Globulin with Baspirin in Kawasaki Disease:A Clinical Study of 93 Cases

Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?

Effect of Early Intravenous Immunoglobulin Therapy in Kawasaki Disease: A Systematic Review and Meta-Analysis

Effectiveness of Initial Corticosteroid Treatment in Kawasaki Disease Children Suspected to be IVIG Resistant

Thinking beyond intravenous immunoglobulin for Kawasaki disease